Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sipuleucel-T

- PMLiVE

NICE U-turn on Novartis’ Afinitor for kidney cancer

Set to back treatment's routine NHS use following offer of discount and new data

- PMLiVE

Merck & Co’s Keytruda muscles further ahead of rivals in lung cancer

Granted accelerated review by FDA for use in combination with chemotherapy

National Institute for Health and Care Excellence NICE logo

NICE recognises Smartinhaler as best practice for asthma care

Digital monitoring device proven to increase adherence and reduce hospital visits

- PMLiVE

Wales unveils ‘sensible’ £80m medicines access fund

New scheme hopes to provide greater consistency and accelerate availability by eight weeks

- PMLiVE

Valeant uncouples Dendreon and skincare brands to cut debt

Agrees deals worth $2.1bn with L’Oreal and Sanpower Group

- PMLiVE

Pfizer/Opko’s long-acting growth hormone misses mark in trial

Previously forecast as a blockbuster product, hGH-CTP fails to show significant change

- PMLiVE

Pfizer joins forces with IBM on immuno-oncology drug discovery

Engages the Watson supercomputer to accelerate research into new cancer therapies

Novartis building

Novartis adds oral eczema drug with Ziarco acquisition

Expands dermatology pipeline with first-in-class, Pfizer-developed treatment prospect

Eli Lilly HQ

Lilly nears EU approval of arthritis drug baricitinib

On course for early 2017 verdict, setting up challenge to Pfizer’s Xeljanz

- PMLiVE

FDA green light for Pfizer’s eczema drug

Blockbuster-hopeful Eucrisa expected to launch early next year at $580 per 60mg tube

IFPMA elects Pfizer’s Ian Read as president

Read succeeds Merck KGaA’s Dr Stefan Oschmann for a two-year term

- PMLiVE

QuintilesIMS launches European oncology data-gathering initiative

Will collaborate with Bristol-Myers Squibb, Lilly, Merck KGaA and Pfizer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links